TLP
CRSP icon

Tri Locum Partners’s CRISPR Therapeutics CRSP Stock Holding History

Tri Locum Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-36,460
Closed -$2.38M – 79
2022
Q3 		$2.38M Buy
+36,460
New +$2.64M 0.65% 33

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Tri Locum Partners's CRSP Position: Q4 2022 in Review

Tri Locum Partners sold out of CRISPR Therapeutics (CRSP) in Q4 2022, closing a stake of 36,460 shares — an estimated $2.38M sold.

Tri Locum Partners first reported a position in CRSP in Q3 2022 and held it in 1 quarter. The position peaked at $2.38M in Q3 2022. 398 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

  • Tri Locum Partners reported no remaining CRISPR Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Tri Locum Partners sold 36,460 CRISPR Therapeutics shares in Q4 2022, an estimated $2.38M.
  • Tri Locum Partners first reported a position in CRISPR Therapeutics in Q3 2022 and held it in 1 quarter.
  • Tri Locum Partners's CRISPR Therapeutics position peaked at $2.38M in Q3 2022.
  • 398 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on Tri Locum Partners's 13F filing for Q4 2022, filed 14 Feb 2023.